Buparlisib | BKM120;NVP-BKM120 | PI3K | AmBeed-信号通路专用抑制剂

首页 / / / PI3K / Buparlisib/布帕尼西

Buparlisib/布帕尼西 {[allProObj[0].p_purity_real_show]}

货号：A105286 同义名： BKM120; NVP-BKM120

Buparlisib (BKM120; NVP-BKM120) 是一种泛 I 类 PI3K 抑制剂，对 p110α 的 IC50 为 52 nM，对 p110β 为 166 nM，对 p110δ 为 116 nM，对 p110γ 为 262 nM。

Buparlisib/布帕尼西化学结构
CAS号：944396-07-0

Buparlisib/布帕尼西 3D分子结构
CAS号：944396-07-0

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Buparlisib/布帕尼西纯度/质量文件产品仅供科研

货号：A105286 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]; • Cell, 2025. Ambeed. [ A122167 ]; • Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]; • Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]; • Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]; 更多 >

PI3K 亚型比较

产品名称	C2β ↓ ↑	p110α ↓ ↑	p110β ↓ ↑	p110γ ↓ ↑	p110δ ↓ ↑	PI3K ↓ ↑	Vps34 ↓ ↑	其他靶点	纯度
A66	+ C2β, IC50: 462 nM	++ p110α, IC50: 32 nM							99%+
Taselisib	+ C2β, IC50: 292 nM	++++ PI3Kα, Ki: 0.29 nM	+++ PI3Kβ, Ki: 9.1 nM	++++ PI3Kγ, Ki: 0.97 nM	++++ PI3Kδ, Ki: 0.12 nM		+ hVps34, IC50: 374 nM		99%+
Gedatolisib		++++ PI3Kα, IC50: 0.4 nM		+++ PI3Kγ, IC50: 5.4 nM				mTOR	99%
HS-173		++++ PI3Kα , IC50: 0.8 nM							99%+
Serabelisib		+++ PI3Kα, IC50: 21 nM							99%+
GNE-477		++++ PI3Kα, IC50: 4 nM						mTOR	99%
YM-201636		+ p110α, IC50: 3.3 μM						PIKfyve	98%
AS-252424		+ PI3Kα, IC50: 935 nM		++ PI3Kγ, IC50: 33 nM					99%
Alpelisib		+++ PI3Kα, IC50: 5 nM							99%+
AS-604850		+ PI3Kα, IC50: 4.5 μM		+ PI3Kγ, IC50: 0.25 μM					99%
SF2523		++ PI3Kα, IC50: 34 nM		++ PI3Kγ, IC50: 158 nM				DNA-PK,mTOR	99%+
Inavolisib		++++ PI3K alpha, IC50: 0.038 nM							99%+
Bimiralisib		++++ PI3Kα, Kd: 1.5 nM	+++ PI3Kβ, Kd: 11 nM	++ PI3Kγ, Kd: 25 nM	++ PI3Kδ, Kd: 25 nM			mTOR	99%+
GSK1059615		++++ PI3Kα, IC50: 0.4 nM	++++ PI3Kβ, IC50: 0.6 nM	+++ PI3Kγ, IC50: 5 nM	++++ PI3Kδ, IC50: 2 nM			mTOR	98%
GSK2636771			✔						99%
Fimepinostat		+++ PI3Kα, IC50: 19 nM	++ PI3Kβ, IC50: 54 nM		++ PI3Kδ, IC50: 39 nM				99%+
VS-5584		++++ PI3Kα, IC50: 2.6 nM	+++ PI3Kβ, IC50: 21 nM	++++ PI3Kγ, IC50: 3.0 nM	++++ PI3Kδ, IC50: 2.7 nM			mTOR	98%
Dactolisib		++++ p110α1, IC50: 4 nM	++ p110β, IC50: 75 nM	+++ p110γ, IC50: 5 nM	+++ p110δ, IC50: 7 nM				98+%
PI-103		++++ p110α, IC50: 2 nM	++++ p110β, IC50: 3 nM	+++ p110γ, IC50: 15 nM	++++ p110δ, IC50: 3 nM			DNA-PK,mTOR	99%+
PI-3065			+ p110β, IC50: 1078 nM		+++ p110δ, IC50: 15 nM				99%+
Voxtalisib		++ PI3Kα, IC50: 39 nM	++ PI3Kβ, IC50: 113 nM	+++ PI3Kγ, IC50: 9 nM	++ PI3Kδ, IC50: 43 nM			DNA-PK,mTOR	99%+
AZD-8835		+++ PI3Kα, IC50: 6.2 nM	+ PI3Kβ, IC50: 431 nM	++ PI3Kγ, IC50: 90 nM	+++ PI3Kδ, IC50: 5.7 nM				99%
Pilaralisib analogue		++ PI3Kα, IC50: 39 nM	++ PI3Kβ, IC50: 36 nM	+++ PI3Kγ, IC50: 23 nM	++ PI3Kδ, IC50: 36 nM				99%+
ZSTK474		+++ PI3Kα, IC50: 16 nM	++ PI3Kβ, IC50: 44 nM	++ PI3Kγ, IC50: 49 nM	+++ PI3Kδ, IC50: 4.6 nM	++ PI3K, IC50: 37 nM			98%
AS-605240		++ PI3Kα, IC50: 60 nM	+ PI3Kβ, IC50: 270 nM	+++ PI3Kγ, IC50: 8 nM	+ PI3Kδ, IC50: 300 nM				98%
TGX-221			+++ p110β, IC50: 5 nM		++ p110δ, IC50: 0.1 μM				99%+
PF-04691502		++++ PI3Kα, Ki: 1.8 nM	++++ PI3Kβ, Ki: 2.1 nM	++++ PI3Kγ, Ki: 1.9 nM	++++ PI3Kδ, Ki: 1.6 nM			mTOR	98+%
GDC-0084		++++ PI3Kα, Ki app: 2 nM	++ PI3Kβ, Ki app: 46 nM	+++ PI3Kγ, Ki app: 10 nM	++++ PI3Kδ, Ki app: 3 nM			mTOR	99%+
Buparlisib		++ p110α, IC50: 52 nM	+ p110β, IC50: 166 nM	+ p110γ, IC50: 262 nM	++ p110δ, IC50: 116 nM		+ Vps34, IC50: 2.4 μM	mTOR	98%
LY294002		+ p110α, IC50: 0.5 μM	+ p110β, IC50: 0.97 μM		+ p110δ, IC50: 0.57 μM			DNA-PK	99%+
AZD 6482		+ PI3Kα, IC50: 870 nM	+++ PI3Kβ, IC50: 10 nM		++ PI3Kδ, IC50: 80 nM			DNA-PK	99%+
Pictilisib		++++ p110α, IC50: 3 nM	++ p110β, IC50: 33 nM	++ p110γ, IC50: 75 nM	++++ p110δ, IC50: 3 nM			mTOR	99%+
PKI-402		++++ PI3Kα, IC50: 2 nM	+++ PI3Kβ, IC50: 7 nM	+++ PI3Kγ, IC50: 16 nM	+++ PI3Kδ, IC50: 14 nM			mTOR	98%
Copanlisib		++++ PI3Kα, IC50: 0.5 nM	++++ PI3Kβ, IC50: 3.7 nM	+++ PI3Kγ, IC50: 6.4 nM	++++ PI3Kδ, IC50: 0.7 nM				99%+
Omipalisib		++++ p110α, Ki: 0.019 nM	++++ p110β, Ki: 0.13 nM	++++ p110γ, Ki: 0.06 nM	++++ p110δ, Ki: 0.024 nM				99%+
Izorlisib		+++ PI3Kα, IC50: 14 nM	++ PI3Kβ, IC50: 0.12 μM	++ PI3Kγ, IC50: 36 nM	+ PI3Kδ, IC50: 0.50 μM				99%+
AZD8186		++ PI3Kα, IC50: 35 nM	++++ PI3Kβ, IC50: 4 nM		+++ PI3Kδ, IC50: 12 nM				99%
KU-0060648		++++ PI3Kα, IC50: 4 nM	++++ PI3Kβ, IC50: 0.5 nM	+ PI3Kγ, IC50: 0.59 μM	++++ PI3Kδ, IC50: 0.1 nM			DNA-PK	98%
Apitolisib		+++ p110α, IC50: 5 nM	++ p110β, IC50: 27 nM	+++ p110γ, IC50: 14 nM	+++ p110δ, IC50: 7 nM			mTOR	98%+
CZC24832			+ PI3Kβ, IC50: 1.1 μM	++ PI3Kγ, IC50: 27 nM					98+%
BGT226 maleate		++++ PI3Kα, IC50: 4 nM	++ PI3Kβ, IC50: 63 nM	++ PI3Kγ, IC50: 38 nM				mTOR	99%+
TG 100713		++ PI3Kα, IC50: 165 nM	+ PI3Kβ, IC50: 215 nM	++ PI3Kγ, IC50: 50 nM	+++ PI3Kδ, IC50: 24 nM				98%+
PI3K-IN-1		++ PI3Kα, IC50: 39 nM	++ PI3Kβ, IC50: 113 nM	+++ PI3Kγ, IC50: 9 nM	++ PI3Kδ, IC50: 43 nM			DNA-PK,mTOR	98+%
TG100-115		+ PI3Kα, IC50: 1.3 μM	+ PI3Kβ, IC50: 1.2 μM	++ PI3Kγ, IC50: 83 nM	+ PI3Kδ, IC50: 235 nM				98%
PIK-90		+++ PI3Kα, IC50: 11 nM	+ PI3Kβ, IC50: 350 nM	+++ PI3Kγ, IC50: 18 nM	++ PI3Kδ, IC50: 58 nM				99%+
PIK-294			+ p110β, IC50: 490 nM	++ p110γ, IC50: 160 nM	+++ p110δ, IC50: 10 nM				99%+
Duvelisib			++++ PI3Kβ, Ki: 1564 pM	++ PI3Kγ, Ki: 243 pM	++++ PI3Kδ, Ki: 23 pM				99%+
GDC-0326		++++ PI3Kα, Ki: 0.2 nM	++ PI3Kβ, Ki: 26.6 nM	+++ PI3Kγ, Ki: 10.2 nM	++++ PI3Kδ, Ki: 4 nM				98%
Quercetin Dihydrate			+ PI3Kβ, IC50: 5.4 μM	+ PI3Kγ, IC50: 2.4 μM	+ PI3Kδ, IC50: 3.0 μM				95%
Quercetin			+ PI3Kβ, IC50: 5.4 μM	+ PI3Kγ, IC50: 2.4 μM	+ PI3Kδ, IC50: 3.0 μM			Src,PKC,Sirtuin	95%
Leniolisib		+ PI3Kα, IC50: 0.244 μM	+ PI3Kβ, IC50: 0.424 μM	+ PI3Kγ, IC50: 2.23 μM	+++ PI3Kδ, IC50: 0.011 μM			DNA-PK	99%+
PIK-108			✔						99%
Eganelisib				+++ PI3Kγ, IC50: 16 nM					99%+
CAY10505				✔					99%
IPI-3063					++++ p110δ, IC50: 2.5 nM				99%
Nemiralisib					++++ PI3Kδ, pKi: 9.9				99%+
PF-4989216		++++ p110α, IC50: 2 nM		++ p110γ, IC50: 65 nM	++++ p110δ, IC50: 1 nM				99%+
PIK-75 HCl		+++ p110α, IC50: 5.8 nM		++ p110γ, IC50: 76 nM	+ p110δ, IC50: 0.51 μM			DNA-PK	99%+
Tenalisib				++ PI3Kγ, IC50: 33.2 nM	++ PI3Kδ, IC50: 24.5 nM				98%
Acalisib					+++ p110δ, IC50: 14 nM				99%+
Umbralisib					+++ PI3Kδ, IC50: 22.2 nM				99%+
AMG319				+ PI3Kγ, IC50: 850 nM	+++ PI3Kδ, IC50: 18 nM				99%
IC-87114				+ PI3Kγ, IC50: 29 μM	+ PI3Kδ, IC50: 0.5 μM				99%+
Idelalisib				++ p110γ, IC50: 89 nM	++++ p110δ, IC50: 2.5 nM				98%
PIK-293				+ p110γ, IC50: 10 μM	+ p110δ, IC50: 0.24 μM				99%+
Vps34-PIK-III					+ PI3Kδ, IC50: 1.2μM		+++ Vps34, IC50: 0.018μM		99%+
GSK2292767					✔				98%
Seletalisib				+ PI3Kγ, IC50: 282 nM	+++ PI3Kδ, IC50: 12 nM				99%+
P110δ-IN-1					++++ P110δ, IC50: 0.6 nM				99%
PI3Kδ-IN-5					++++ PI3Kδ, IC50: 0.9 nM				99%
SRX3207		+ PI3K alpha, IC50: 244 nM		+ PI3K gamma, IC50: 9790 nM	+ PI3K delta, IC50: 388 nM			Syk	98%
Parsaclisib HCl					++++ PI3Kδ, IC50: 1 nM				98%
IHMT-PI3Kδ-372					+++ PI3Kδ, IC50: 14 nM				98%
Trigonelline						✔		Akt	99%+
Wortmannin						++++ PI3K, IC50: 3 nM		MLCK,DNA-PK	99%+
Samotolisib						✔		DNA-PK	99%+
GNE-317						✔			99%+
Oroxin B						✔		Akt,PTEN	99%+
NU 7026						+ PI3K, IC50: 13 μM		DNA-PK	98+%
Deguelin						✔		Akt	99%+
Ailanthone						✔		Akt,CDK,ATM/ATR	98%
Resibufogenin						✔		ROS	98%
KU-57788						+ PI3K, IC50: 5 μM		DNA-PK,mTOR	99%+
Cinobufagine						✔		Akt	99%
α-Linolenic acid						✔			97% (GC)
MTX-211						✔		EGFR	98%
PI3K/mTOR Inhibitor-2						++++ PI3K, IC50: 3.4 nM		mTOR	99%+
SPP-86						✔			99%+
(E)-Akt inhibitor-IV						✔			98%
Vps34-IN-1							++ Vps34, IC50: 25 nM		98%
SAR405							++++ Vps34, IC50: 1.2 nM		98+%
3-Methyladenine				+ PI3Kγ, IC50: 60 μM			+ Vps34, IC50: 25 μM	Autophagy	98%
Vps34-IN-4							+++ VPS34, IC50: 15 nM		98%+
Autophinib							+++ Vps34, IC50: 19 nM	Autophagy	99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Buparlisib/布帕尼西生物活性

靶点	p110γ p110γ, IC50:262 nM p110β p110β, IC50:166 nM p110α p110α, IC50:52 nM p110δ p110δ, IC50:116 nM Vps34 Vps34, IC50:2.4 μM
描述	PI3Ks (Phosphatidylinositol-4,5-bisphosphate 3-kinase) participate in a diverse array of process, including the regulation of cellular survival, differentiation and stem cell-like properties, growth, proliferation, metabolism, migration, and angiogenesis^[2]. BKM120 is an orally bioavailable pan-PI3K inhibitor with IC50 value of IC50=52nM, IC50=116nM, IC50=166nM, IC50=262nM, IC50=2.4μM, IC50=4.6μM on p110α, p110δ, p110β, p110γ(measured by filter binding assay), Vps34 (measured by ATP depletion assay), mTOR (measured by TR-FRET assay), respectively, most potent on Class I PI3Ks. Treatment of BKM120 can cause decrease of p-AKT-ser473 (downstream of PI3Ks) both in vitro and in vivo. BKM120 has good pharmacokinetic properties, exhibiting medium to high oral bioavailability across species as 80%, 50%, 44% and 100% observed in mouse, rat, dog, and monkey, respectively^[1]. For BKM120 is well-tolerated and permeable to the blood–brain barrier, it is the most frequently-used PI3K inhibitor in the clinical trials for glioblastoma multiforme treatment^[3].
作用机制	Mechanism: BKM120 has greater affinity for the free PI3K enzyme,relative to the ATP bound.^[4]

Buparlisib/布帕尼西细胞实验

Cell Line MDA-MB-453 cells BT20 cells HER2+/PIK3CAH1047R primary tumor cells HCC1954 cells MDA-MB 453 cells H10 cells H3 cells H2 cells H1 cells WHIM12 cells WHIM12 cells C-26 tumor cells H460 cells WHIM12 cells WHIM12 cells	Concentration	Treated Time	Description	References
MDA-MB-453 cells	0.5 µM	48 h	Induced apoptosis	Theranostics. 2021 Jan 20;11(8):3552-3564.
BT20 cells	0.5 µM	48 h	Induced apoptosis	Theranostics. 2021 Jan 20;11(8):3552-3564.
HER2+/PIK3CAH1047R primary tumor cells	1 μM	24 h	Evaluate the effect of Buparlisib on primary tumor cells, showing upregulation of ECM gene expression	Cancer Res. 2017 Jun 15;77(12):3280-3292.
HCC1954 cells	1 μM	24 h	Evaluate the effect of Buparlisib on HER2+ breast cancer cells, showing upregulation of ECM gene expression	Cancer Res. 2017 Jun 15;77(12):3280-3292.
MDA-MB 453 cells	1 μM	24 h	Evaluate the effect of Buparlisib on HER2+ breast cancer cells, showing upregulation of ECM gene expression	Cancer Res. 2017 Jun 15;77(12):3280-3292.
H10 cells	10 µM	72 h	To assess the effect of Buparlisib on cell viability, results showed that Buparlisib significantly reduced cell viability.	Int J Mol Sci. 2019 Aug 29;20(17):4235.
H3 cells	10 µM	72 h	To assess the effect of Buparlisib on cell viability, results showed that Buparlisib significantly reduced cell viability.	Int J Mol Sci. 2019 Aug 29;20(17):4235.
H2 cells	10 µM	72 h	To assess the effect of Buparlisib on cell viability, results showed that Buparlisib significantly reduced cell viability.	Int J Mol Sci. 2019 Aug 29;20(17):4235.
H1 cells	10 µM	72 h	To assess the effect of Buparlisib on cell viability, results showed that Buparlisib significantly reduced cell viability.	Int J Mol Sci. 2019 Aug 29;20(17):4235.
WHIM12 cells	0-1 uM	24 h	To evaluate the cytotoxic effect of Buparlisib in combination with other drugs on WHIM12 cells, results showed synergistic anti-tumor effects.	Cancer Res. 2018 May 15;78(10):2732-2746.
WHIM12 cells	1 uM	6 days	To evaluate the effect of Buparlisib on the growth of WHIM12 cells, results showed that Buparlisib significantly inhibited cell growth.	Cancer Res. 2018 May 15;78(10):2732-2746.
C-26 tumor cells	2.5 μM and 5 μM	72 h	To evaluate the effect of buparlisib on the growth of C-26 tumor cells, results showed that buparlisib significantly reduced tumor growth.	Mol Cancer Ther. 2017 Feb;16(2):344-356.
H460 cells	1 μM	24 h	Buparlisib reduced glucose consumption in H460 cells by inhibiting the PI3K signaling pathway.	Nat Commun. 2019 Nov 29;10(1):5444.
WHIM12 cells	0-1 μM		To evaluate the cytotoxic effect of Buparlisib on WHIM12 cells, results showed that Buparlisib in combination with other drugs had synergistic or additive cytotoxic effects.	Cancer Res. 2018 May 15;78(10):2732-2746.
WHIM12 cells	1 μM	6 days	To evaluate the effect of Buparlisib on the clonogenic ability of WHIM12 cells, results showed that Buparlisib significantly inhibited colony formation.	Cancer Res. 2018 May 15;78(10):2732-2746.

Buparlisib/布帕尼西动物实验

Species Nude mice Mice NOD/SCID mice Mice Mice NSG mice Mice Mice	Animal Model HER2+/PIK3CAH1047R transgenic mammary tumor model TNBC cell line xenograft model Subcutaneous H1_DL2 tumor model PDX model TNBC PDX models BT20 xenograft model Colon-26 tumor model Patient-derived xenograft models of TNBC	Administration	Dosage	Frequency	Description	References
Nude mice	HER2+/PIK3CAH1047R transgenic mammary tumor model	Oral gavage	30 mg/kg	Once daily for over 3 weeks	Evaluate the effect of Buparlisib on HER2+/PIK3CAH1047R tumors, showing resistance to combination therapy	Cancer Res. 2017 Jun 15;77(12):3280-3292.
Mice	TNBC cell line xenograft model	Oral	30 mg/kg	Once daily for 7 days	Combination treatment resulted in a ~40% decrease in tumor volume after 7 days, while tumors in single agent groups showed slight growth. The combination significantly reduced lung metastatic burden.	NPJ Breast Cancer. 2017 Apr 26;3:17
NOD/SCID mice	Subcutaneous H1_DL2 tumor model	Oral	50 mg/kg	Once daily for 30 days	To assess the effect of Buparlisib on tumor growth, results showed that Buparlisib significantly inhibited tumor growth.	Int J Mol Sci. 2019 Aug 29;20(17):4235.
Mice	PDX model	Oral	20 mg/kg	Once daily, 5 days/week for 3 weeks	To test the growth inhibitory effect of buparlisib on PIK3R1W624R PDXs, results showed that buparlisib delayed tumor growth.	Cells. 2020 Feb 14;9(2):442
Mice	TNBC PDX models	Oral gavage	30mg/kg	Days 1-5 each week for 24-32 days	To evaluate the effect of Buparlisib on tumor growth in TNBC PDX models, results showed varying responsiveness across models, with some exhibiting resistance.	Cancer Res. 2018 May 15;78(10):2732-2746.
NSG mice	BT20 xenograft model	Intraperitoneal injection	25 mg/kg	Once daily for 2 weeks	Inhibited tumor growth and metastasis	Theranostics. 2021 Jan 20;11(8):3552-3564.
Mice	Colon-26 tumor model	Oral	25 mg/kg	Daily for 16 days	To evaluate the effect of buparlisib on the growth of C-26 tumors, results showed that buparlisib significantly reduced tumor growth and preserved skeletal muscle mass.	Mol Cancer Ther. 2017 Feb;16(2):344-356.
Mice	Patient-derived xenograft models of TNBC	Oral	30 mg/kg	Days 1-5 each week for 24-32 days	To evaluate the antitumor effect of Buparlisib on PDX models, results showed significant variability in response among different models, with some models exhibiting resistance to Buparlisib.	Cancer Res. 2018 May 15;78(10):2732-2746.

Buparlisib/布帕尼西动物研究

Dose	Nude Mice: min = 2 mg/kg, max = 20 mg/kg^[5] Mice: min = 30 mg/kg, max = 60 mg/kg^[4]
Administration	p.o., i.v., i.p.

Buparlisib/布帕尼西临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT01820364	Melanoma	Phase 2	Terminated(Study was withdrawn... 展开 >> due to scientific and business considerations.) 收起 <<	-	United States, Tennessee ... 展开 >> Sarah Cannon Research Institute Onc Dept Nashville, Tennessee, United States, 37203 Australia, Victoria Novartis Investigative Site East Melbourne, Victoria, Australia, 3002 Canada, Alberta Novartis Investigative Site Edmonton, Alberta, Canada, T6G 1Z2 Germany Novartis Investigative Site Heidelberg, Germany, 69120 Spain Novartis Investigative Site Barcelona, Catalunya, Spain, 08035 Switzerland Novartis Investigative Site Zuerich, Switzerland, 8091 收起 <<
NCT01820364	-		Terminated(Study was withdrawn... 展开 >> due to scientific and business considerations.) 收起 <<	-	-
NCT02159066	Melanoma	Phase 2	Active, not recruiting	March 30, 2019	United States, Arizona ... 展开 >> Mayo Clinic - Arizona onc Dept Scottsdale, Arizona, United States United States, California University of California at Los Angeles Onc Dept Los Angeles, California, United States, 90095 United States, Massachusetts Massachusetts General Hospital Dept of Onc. Boston, Massachusetts, United States, 02115 United States, New York Memorial Sloan Kettering Cancer Center Dept Oncology New York, New York, United States, 90033 United States, Oregon Oregon Health & Science University Onc. Dept Portland, Oregon, United States, 97239 United States, Tennessee Sarah Cannon Research Institute Onc. Dept Nashville, Tennessee, United States, 37203 Australia, Victoria Array BioPharma Investigative Site East Melbourne, Victoria, Australia, 3002 Canada, Ontario Array BioPharma Investigative Site Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec Array BioPharma Investigative Site Montreal, Quebec, Canada, H3T 1E2 Germany Array BioPharma Investigative Site Heidelberg, Germany, 69120 Array BioPharma Investigative Site Köln, Germany, 50937 Array BioPharma Investigative Site Muenchen, Germany, 80336 Array BioPharma Investigative Site Würzburg, Germany, 97080 Italy Array BioPharma Investigative Site Napoli, Italy, 80131 Netherlands Array BioPharma Investigative Site Amsterdam, Netherlands, 1066 CX Spain Array BioPharma Investigative Site Barcelona, Catalunya, Spain, 08035 Switzerland Array BioPharma Investigative Site Zuerich, Switzerland, 8091 United Kingdom Array BioPharma Investigative Site Oxford, United Kingdom, OX3 7LJ 收起 <<

Buparlisib/布帕尼西参考文献

[1]Burger MT, Pecchi S, et al. Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer. ACS Med Chem Lett. 2011;2(10):774-9.

[2]Vanhaesebroeck B, Guillermet-Guibert J, et al. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010;11(5):329-41.

[3]Zhao HF, Wang J, et al. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. Mol Cancer. 2017;16(1):100.

[4]Maira SM, Pecchi S, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther. 2012;11(2):317-28.

[5]Speranza MC, Nowicki MO, et al. BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma. Sci Rep. 2016 Feb 5;6:20189.

Buparlisib/布帕尼西实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.44mL

0.49mL

0.24mL

12.18mL

2.44mL

1.22mL

24.37mL

4.87mL

2.44mL

Buparlisib/布帕尼西技术信息

CAS号	944396-07-0
分子式	C₁₈H₂₁F₃N₆O₂
分子量	410.39
SMILES Code	NC1=NC=C(C2=CC(=NC(=N2)N2CCOCC2)N2CCOCC2)C(=C1)C(F)(F)F
MDL No.	MFCD18251596

别名	BKM120; NVP-BKM120
运输	蓝冰
InChI Key	CWHUFRVAEUJCEF-UHFFFAOYSA-N
Pubchem ID	16654980

存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Inert atmosphere, store in freezer, under -20°C

溶解方案

细胞实验：

DMSO: 105 mg/mL(255.85 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

方案三

方案四

方案五

配制的工作液建议现用现配，短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

大规格询价

* 公司或机构名称：

* 姓名：

* 电话：

* 邮箱： * 国家/区域： * 需求量：

* 货号：

* CAS号：

* 产品名称：在线留言：

请填写此表格索取QC报告。我们很快就会发送到您的邮箱。您的信息在我们这里是安全的。*是必填项.

产品名称： * 货号：

* 姓名：

* 电话：

* 邮箱： * 公司或机构名称： * 部门：留言给我们：

摩尔计算器

计算溶液所需的质量，体积或浓度。 Ambeed 摩尔浓度计算器基于以下方程式：

浓度 (mol/L) × 体积 (L) × 分子量 (g/mol)=质量 (g)

浓度

体积

分子量

质量

*在制备母液时，请始终参考产品标签或 MSDS / COA（在产品页面可下载）上所显示的对应批次产品的分子量。

靶点

靶点	数值

p110γ	p110γ, IC50:262 nM
p110β	p110β, IC50:166 nM
p110α	p110α, IC50:52 nM
p110δ	p110δ, IC50:116 nM
Vps34	Vps34, IC50:2.4 μM

总药量计算器

动物实验：给药剂量 mg/kg 动物体重 g 动物数量只每天给药次给药天

需要的总药量： mg

工作液计算器

动物实验：给药剂量 mg/kg 动物体重 g 给药体积 μL

您需要配制的工作液浓度为：mg/mL

细胞研究

细胞系	浓度	检测类型	检测时间	活性说明	数据源

786-0	1-20μM	Growth Inhibition Assay	72h	IC50＜1μM	23479136
A2780		Cytotoxic Assay	72 h	Cytotoxicity against PTEN-deficient human A2780 cells with GI50 of 0.000635 μM	24900266
A2780		Function Assay	1 h	Inhibition of PI3K-mediated AKT Ser473 phosphorylation with EC50 of 0.055 μM	24900266
A2780		Function Assay	1 h	Inhibition of PI3K-mediated AKT Ser473 phosphorylation in PTEN-deficient human A2780 cells with EC50 of 0.074 μM	24900266
A2780		Growth Inhibition Assay	72 h	EC50=0.52 μM	24900266
A549	500 nM	Function Assay	48 h	Inhibits Akt activation	25937299
A549	1 μM	Growth Inhibition Assay	72 h	Inhibits cell growth	25937299
AGS		Growth Inhibition Assay	72h	IC50=1.714±0.117μM	22159814
ARP-1	10μM	Apoptosis Assay	24h	induces MM cell apoptosis through caspase activation	22207485
BCR-ABL	0.25-10μM	Growth Inhibition Assay	4d	significantly inhibit cell proliferation	24244612
BNL	1 μM	Function Assay	1 h	Inhibits phosphorylation of S6	25004403
BON	1-5μM	Growth Inhibition Assay	72h	decreases cell proliferation	24443523
BON	1-5μM	Apoptosis Assay	24h	increases apoptosis	24443523
BON-1	500 nM	Growth Inhibition Assay	10 d	Inhibits cell growth	25026292
BON-1	500 nM	Function Assay	4 h	Inhibits phosphorylation of AKT at Thr308 and Ser473	25026292
BSY-1	10 μM	Apotosis Assay	48 h	Induces apoptosis in BSY-1 cells harbouring PIK3CA hotspot mutation	25152245
BT-20	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
BT-474	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
BT-549	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
colon cancer cell lines	0-10μM	Growth Inhibition Assay	72h	IC50=1μM	22543857
DU145		Cytotoxic Assay	72 h	Cytotoxicity against human DU145 cells expressing LKB1 mutant with GI50 of 0.000435 μM	24900266
DU145		Function Assay	1 h	Inhibition of PI3K-mediated AKT Ser473 phosphorylation in human DU145 cells harboring LKB1 mutation with EC50 of 0.073 μM	24900266
EFM-19	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
EFM-192A	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
EHEB	0.2-20μM	Cytotoxicity assay	72h	IC50=0.7μM	23238639
EMT6	5 μM	Function Assay	24 h	Reduces oxygen consumption	24631147
FaDu	5 μM	Function Assay	24 h	Reduces oxygen consumption	24631147
gastric cancer cell lines	0-10μM	Growth Inhibition Assay	72h	IC50=2-5μM	22543857
GBM	2μM	Apoptosis Assay	48h	induced higher levels of apoptosis, and decreased cell viability	24500492
glioma cell lines		Growth Inhibition Assay	72h	IC50=1-2μM	22065080
H1975	0.3-9.6μM	Growth Inhibition Assay	72h	IC50=1.385μM	24337846
H1975	2μM	Apoptosis Assay	24h	increases apoptosis rate significantly	24337846
H522	1 μM	Growth Inhibition Assay	72 h	Inhibits cell growth	25937299
H596	1 μM	Function Assay		Impairs cell migration	26013318
HBC-5	10 μM	Apotosis Assay	48 h	Induces apoptosis	25152245
HCC1143	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
HCC1187	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
HCC1419	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
HCC1500	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
HCC1806	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
HCC1937	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
HCC202	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
HCC2218	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
HCC2450	1 μM	Function Assay		Impairs cell invasion	26013318
HCC38	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
HCT116	5 μM	Function Assay	24 h	Reduces oxygen consumption	24631147
HCT-116	10 μM	Apotosis Assay	48 h	Induces apoptosis in HCT-116 cells harbouring PIK3CA hotspot mutation	25152245
HCT-116/HT-29/MKN-45	2μM	Apoptosis Assay	48h	shift in G2 phase	22543857
HCT-15	10 μM	Apotosis Assay	48 h	Induces apoptosis in HCT-15 cells harbouring PIK3CA hotspot mutation	25152245
Hs578T	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
HT-29 and HCT-116	5μM	Caspase assay	24h	induces caspase activity	22543857
Huh7	1 μM	Function Assay	1 h	Inhibits phosphorylation of AKT at Ser474	25004403
Huh7	1μM	Kinase Assay	48h	signiﬁcantly reduces phosphorylation of Akt	23489999
human HCC cell lines	0.005-1μM	Cell viability assay	48h	IC50=1μM	23489999
human NSCLC	0.5-2μM	Growth Inhibition Assay	72h	IC50=1μM	22781393
human NSCLC	1μM	Kinase Assay	24h	inhibits the Akt/mTOR signaling pathway at 3h after treatment	22781393
human NSCLC cell lines	0.125-4μM	Apoptosis Assay	24h	IC50s ranges from 0.4-2μM	23562472
JIMT-1	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
JVM2	0.2-20μM	Cytotoxicity assay	72h	IC50=0.9μM	23238639
KPL-1	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
LC-1/SQSF	3μM	Function Assay	24h	decrease NRF2 protein level	23980093
LN18	20 μM	Growth Inhibition Assay	72 h	IC50<5 μM	24741074
LN18	5 μM	Function Assay	24 h	Inhibits phosphorylation of AKT	24741074
LN229	20 μM	Growth Inhibition Assay	72 h	IC50<5 μM	24741074
LNCaP	1 μM	Function Assay		Suppresses p-AKT levels	25360799
LNCaP95	1 μM	Function Assay		Suppresses p-AKT levels	25360799
LNZ308	20 μM	Growth Inhibition Assay	72 h	IC50<5 μM	24741074
LNZ308	5 μM	Function Assay	24 h	Inhibits phosphorylation of AKT	24741074
MCF7		Cytotoxic Assay	72 h	Cytotoxicity against human MCF7 cells expressing PI3Kalpha E545K mutant with GI50 of 0.000158 μM	24900266
MCF7		Function Assay	1 h	Inhibition of PI3Kalpha E545K mutant-mediated AKT Ser473 phosphorylation with EC50 of 0.1 μM	24900266
MCF7	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
MCF7-myr-Akt	GI50=299±68nM，LD50＞10,000nM	Growth Inhibition Assay	72h	GI50=299±68nM，LD50＞10,000nM	22653967
MDA-MB-134	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
MDA-MB-175	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
MDA-MB-361	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
MDA-MB-415	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
MDA-MB-435	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
MDA-MB-453	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
MDA-MB-468	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
MEC2	0.2-20μM	Cytotoxicity assay	72h	IC50=0.7μM	23238639
MG-63	50 μM	Function Assay	48 h	Inhibits cell invasion	24727660
MG-63	50 μM	Function Assay	48 h	Inhibits matrix metalloproteinase-2 expression	24727660
MG-63	50 μM	Growth Inhibition Assay	48 h	Inhibits cell viability	24727660
MKN-1	10 μM	Apotosis Assay	48 h	Induces apoptosis in MKN-1 cells harbouring PIK3CA hotspot mutation	25152245
MKN-45	10 μM	Apotosis Assay	48 h	Induces apoptosis	25152245
MM cell lines	10μM	Growth Inhibition Assay	24h	IC50 varies among different cell lines in time and dose dependence	22207485
NCI-H460	10 μM	Apotosis Assay	48 h	Induces apoptosis in NCI-H460 cells harbouring PIK3CA hotspot mutation	25152245
NCI-H522	10 μM	Apotosis Assay	48 h	Induces apoptosis	25152245
OVCAR-3	10 μM	Apotosis Assay	48 h	Induces apoptosis	25152245
PIK3CA-mutant MCF7	GI50=160±91nM，LD50=980±273nM	Growth Inhibition Assay	72h	GI50=160±91nM，LD50=980±273nM	22653967
PIK3CA-mutant MCF7	IC50=114±3nM	Kinase Assay	72h	IC50=114±3nM in reducing Akt phosphorylation levels	22653967
primary B-CLL lymphocytes	IC50 for each primary cell line	Apoptosis Assay	24h	IC50＜3μM for all patients	23238639
primary B-CLL lymphocytes	IC50 for each primary cell line	Kinase Assay	24h	inhibits p70S6K & 4E-BP1 expression	23238639
Primary CLL cells	1-10μM	Apoptosis Assay	48h	induces apoptosis in CLL cells independent of prognostic markers	23850807
Primary CLL cells	2μM	Kinase Assay	30min	decreased PI3K activity	23850807
Primary CLL cells	2μM	Cytotoxic Assay	24h	induces cell cytotoxicity	23850807
QGP-1	500 nM	Function Assay	4 h	Inhibits phosphorylation of AKT at Thr308 and Ser473	25026292
RXF-631L	10 μM	Apotosis Assay	48 h	Induces apoptosis	25152245
Saos-2	50 μM	Function Assay	48 h	Inhibits cell invasion	24727660
Saos-2	50 μM	Function Assay	48 h	Inhibits matrix metalloproteinase-2 expression	24727660
Saos-2	50 μM	Growth Inhibition Assay	48 h	Inhibits cell viability	24727660
SJSA-1	50 μM	Function Assay	48 h	Inhibits cell invasion	24727660
SJSA-1	50 μM	Function Assay	48 h	Inhibits matrix metalloproteinase-2 expression	24727660
SJSA-1	50 μM	Growth Inhibition Assay	48 h	Inhibits cell viability	24727660
SK-BR-3	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
SK-HEP1	1-20μM	Growth Inhibition Assay	72h	IC50＜1μM	23479136
SKMES-1	1 μM	Cytotoxic Assay	72 h	Induces cell death	26013318
SKOV-3	10 μM	Apotosis Assay	48 h	Induces apoptosis in SKOV-3 cells harbouring PIK3CA hotspot mutation	25152245
SNU-1		Growth Inhibition Assay	72h	IC50=1.082±0.028μM	22159814
SNU-16		Growth Inhibition Assay	72h	IC50=1.573±0.001μM	22159814
SNU-216		Growth Inhibition Assay	72h	IC50=2.692±0.082μM	22159814
SNU-484		Growth Inhibition Assay	72h	IC50=1.728±0.045μM	22159814
SNU-5		Growth Inhibition Assay	72h	IC50=1.351±0.091μM	22159814
SNU-601		Growth Inhibition Assay	72h	IC50=0.816±0.063μM	22159814
SNU-620		Growth Inhibition Assay	72h	IC50=2.939±0.001μM	22159814
SNU-638		Growth Inhibition Assay	72h	IC50=2.282±0.053μM	22159814
SNU-668		Growth Inhibition Assay	72h	IC50=1.579±0.074μM	22159814
SNU-719		Growth Inhibition Assay	72h	IC50=3.037±0.032μM	22159814
SUM-225	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
T-47D	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
T98G	20 μM	Growth Inhibition Assay	72 h	IC50<5 μM	24741074
T-ALL	between 1.4 and 5.3 mM at 24h and 0.9 and 5.5 mM at 48h in different cell line	Apoptosis Assay	24 or 48h	affects the PI3K pathway in T-ALL cell lines	24310736
U87	20 μM	Growth Inhibition Assay	72 h	IC50<5 μM	24741074
U87	5 μM	Function Assay	24 h	Reduces oxygen consumption	24631147
U87	2μM	Apoptosis Assay	72h	induces cell apoptosis and cleaved PARP and caspase-3	22065080
U87MG		Cytotoxic Assay	72 h	Cytotoxicity against PTEN-deficient human U87MG cells with GI50 of 0.000698 μM	24900266
U87MG		Function Assay	1 h	Inhibition of PI3K-mediated AKT Ser473 phosphorylation in PTEN-deficient human U87MG cells with EC50 of 0.13 μM	24900266
UACC-732	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
UACC-812	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
Y1 cell line	0.1μM/1μM	Growth Inhibition Assay	24h	inhibits 60％ cell viability in Myc-Sctr-transfected cells	22692904
ZR-75-1	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796
ZR-75-30	1 μM	Growth Inhibition Assay	5 d	IC50<1 μM	24879796

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT01820364	Melanoma	Phase 2	Terminated(Study was withdrawn... 展开 >> due to scientific and business considerations.) 收起 <<	-	United States, Tennessee ... 展开 >> Sarah Cannon Research Institute Onc Dept Nashville, Tennessee, United States, 37203 Australia, Victoria Novartis Investigative Site East Melbourne, Victoria, Australia, 3002 Canada, Alberta Novartis Investigative Site Edmonton, Alberta, Canada, T6G 1Z2 Germany Novartis Investigative Site Heidelberg, Germany, 69120 Spain Novartis Investigative Site Barcelona, Catalunya, Spain, 08035 Switzerland Novartis Investigative Site Zuerich, Switzerland, 8091 收起 <<
NCT01820364	-		Terminated(Study was withdrawn... 展开 >> due to scientific and business considerations.) 收起 <<	-	-
NCT02159066	Melanoma	Phase 2	Active, not recruiting	March 30, 2019	United States, Arizona ... 展开 >> Mayo Clinic - Arizona onc Dept Scottsdale, Arizona, United States United States, California University of California at Los Angeles Onc Dept Los Angeles, California, United States, 90095 United States, Massachusetts Massachusetts General Hospital Dept of Onc. Boston, Massachusetts, United States, 02115 United States, New York Memorial Sloan Kettering Cancer Center Dept Oncology New York, New York, United States, 90033 United States, Oregon Oregon Health & Science University Onc. Dept Portland, Oregon, United States, 97239 United States, Tennessee Sarah Cannon Research Institute Onc. Dept Nashville, Tennessee, United States, 37203 Australia, Victoria Array BioPharma Investigative Site East Melbourne, Victoria, Australia, 3002 Canada, Ontario Array BioPharma Investigative Site Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec Array BioPharma Investigative Site Montreal, Quebec, Canada, H3T 1E2 Germany Array BioPharma Investigative Site Heidelberg, Germany, 69120 Array BioPharma Investigative Site Köln, Germany, 50937 Array BioPharma Investigative Site Muenchen, Germany, 80336 Array BioPharma Investigative Site Würzburg, Germany, 97080 Italy Array BioPharma Investigative Site Napoli, Italy, 80131 Netherlands Array BioPharma Investigative Site Amsterdam, Netherlands, 1066 CX Spain Array BioPharma Investigative Site Barcelona, Catalunya, Spain, 08035 Switzerland Array BioPharma Investigative Site Zuerich, Switzerland, 8091 United Kingdom Array BioPharma Investigative Site Oxford, United Kingdom, OX3 7LJ 收起 <<
NCT01934361	Recurrent Glioblastoma Multifo... 展开 >>rme 收起 <<	Phase 1	Completed	-	United States, Arizona ... 展开 >> Barrow Neurological Insitute St. Joseph's Hospital Phoenix, Arizona, United States, 85013 United States, Arkansas Highlands Oncology Group Fayetteville, Arkansas, United States, 72703 United States, Illinois Northwestern University Chicago, Illinois, United States, 60611 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Texas MD Anderson Cancer Center/University of Texas Houston, Texas, United States, 77030 Australia, Victoria Novartis Investigative Site Heidelberg, Victoria, Australia, 3084 Novartis Investigative Site Parkville, Victoria, Australia, 3050 Belgium Novartis Investigative Site Leuven, Belgium, 3000 Canada, Ontario Novartis Investigative Site Toronto, Ontario, Canada, M5G 1Z6 France Novartis Investigative Site Marseille Cedex 05, France, 13885 Novartis Investigative Site Paris Cedex 13, France, 75651 Novartis Investigative Site Saint Herblain cedex, France, 44805 Spain Novartis Investigative Site Barcelona, Catalunya, Spain, 08036 Novartis Investigative Site Hospitalet de LLobregat, Catalunya, Spain, 08907 收起 <<
NCT02154776	Advanced or Metastatic Breast ... 展开 >>Cancer 收起 <<	Phase 1	Completed	-	United States, California ... 展开 >> University of California at Los Angeles UCLA SC Los Angeles, California, United States, 90095 United States, Indiana Horizon Oncology Center SC Lafayette, Indiana, United States, 47905 United States, South Carolina Medical University of South Carolina SC Charleston, South Carolina, United States, 29425 United States, Texas South Texas Accelerated Research Therapeutics SC San Antonio, Texas, United States, 78922 United States, Utah University of Utah / Huntsman Cancer Institute SC-3 Salt Lake City, Utah, United States, 84103 Spain Novartis Investigative Site Madrid, Spain, 28007 收起 <<
NCT01300962	Metastatic Breast Cancer	Phase 1	Active, not recruiting	December 2018	United States, North Carolina ... 展开 >> Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States, 27599 Duke Comprehensive Cancer Center Durham, North Carolina, United States, 27710 收起 <<
NCT01132664	Metastatic Breast Cancer ... 展开 >> HER2+ Breast Cancer 收起 <<	Phase 1 Phase 2	Terminated(Due to the rare pat... 展开 >>ient population and challenges to enroll patients.) 收起 <<	-	United States, Alabama ... 展开 >> University of Alabama at Birmingham/ Kirklin Clinic Univ AL - PI Birmingham, Alabama, United States, 35294-0006 United States, Arkansas Highlands Oncology Group Dept of Highlands Oncology Grp Fayetteville, Arkansas, United States, 72703 United States, Florida H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida, United States, 33612 United States, Michigan Karmanos Cancer Institute Dept.of KarmanosCancerInst (6) Detroit, Michigan, United States, 48201 United States, Missouri Washington University School Of Medicine-Siteman Cancer Ctr WA Siteman St. Louis, Missouri, United States, 63110 United States, New York Beth Israel Medical Center BIMC New York, New York, United States, 10003 United States, Tennessee Sarah Cannon Research Institute Sarah Cannon Cancer Center SC Nashville, Tennessee, United States, 37203 Belgium Novartis Investigative Site Liege, Belgium, 4000 Novartis Investigative Site Wilrijk, Belgium, 2610 France Novartis Investigative Site Lyon Cedex, France, 69373 Novartis Investigative Site Saint-Herblain Cédex, France, 44805 Italy Novartis Investigative Site Cagliari, CA, Italy, 09134 Novartis Investigative Site Macerata, MC, Italy, 62100 Novartis Investigative Site Modena, MO, Italy, 41100 Novartis Investigative Site Terni, TR, Italy, 05100 Spain Novartis Investigative Site Barcelona, Catalunya, Spain, 08035 Novartis Investigative Site Hospitalet de LLobregat, Catalunya, Spain, 08907 Novartis Investigative Site Valencia, Comunidad Valenciana, Spain, 46010 United Kingdom Novartis Investigative Site Brighton, East Sussex, United Kingdom, BN2 5BE Novartis Investigative Site Nottingham, United Kingdom, NG5 1PB Novartis Investigative Site Oxford, United Kingdom, OX3 7LJ 收起 <<
NCT01132664	-		Terminated(Due to the rare pat... 展开 >>ient population and challenges to enroll patients.) 收起 <<	-	-
NCT01285466	Metastatic or Locally Advanced... 展开 >> Solid Tumors 收起 <<	Phase 1	Completed	-	Belgium ... 展开 >> Novartis Investigative Site Bruxelles, Belgium, 1000 Novartis Investigative Site Bruxelles, Belgium, 1200 Novartis Investigative Site Wilrijk, Belgium, 2610 Germany Novartis Investigative Site Essen, Germany, 45147 Novartis Investigative Site Köln, Germany, 50937 Netherlands Novartis Investigative Site Amsterdam, Netherlands, 1066 CX Spain Novartis Investigative Site Sevilla, Andalucia, Spain, 41013 Novartis Investigative Site Barcelona, Catalunya, Spain, 08035 Switzerland Novartis Investigative Site Chur, Switzerland, 7000 Novartis Investigative Site St. Gallen, Switzerland, 9007 收起 <<
NCT02058381	Pre-menopausal Breast Cancer ... 展开 >> PI3K Pathway Inhibition 收起 <<	Phase 1	Completed	-	Hong Kong ... 展开 >> Novartis Investigative Site Hong Kong, Hong Kong Korea, Republic of Novartis Investigative Site Seongnam-si, Gyeonggi-do, Korea, Republic of, 13620 Novartis Investigative Site Gyeonggi-do, Korea, Korea, Republic of, 10408 Novartis Investigative Site Seoul, Korea, Korea, Republic of, 05505 Novartis Investigative Site Seoul, Korea, Korea, Republic of, 06351 Novartis Investigative Site Seoul, Korea, Republic of, 03722 Taiwan Novartis Investigative Site Kuei-Shan Chiang, Taoyuan/ Taiwan ROC, Taiwan, 33305 Novartis Investigative Site New Taipei City, TWN, Taiwan, 23561 Novartis Investigative Site Kaohsiung City, Taiwan, 83301 Novartis Investigative Site Taichung, Taiwan, 407 Novartis Investigative Site Taipei, Taiwan, 10002 Novartis Investigative Site Taipei, Taiwan, 10449 Novartis Investigative Site Taipei, Taiwan, 112 Thailand Novartis Investigative Site Bangkok, Thailand, 10330 Novartis Investigative Site Chiang Mai, Thailand, 50200 收起 <<
NCT01971489	Adult Solid Neoplasm ... 展开 >> Recurrent Non-Small Cell Lung Carcinoma Stage IIIA Non-Small Cell Lung Cancer Stage IIIB Non-Small Cell Lung Cancer Stage IV Non-Small Cell Lung Cancer 收起 <<	Phase 1	Withdrawn	-	United States, New York ... 展开 >> Roswell Park Cancer Institute Buffalo, New York, United States, 14263 收起 <<
NCT01923168	Breast Cancer	Phase 2	Completed	-	-
NCT01730248	Myelofibrosis	Phase 1	Completed	-	Australia, Queensland ... 展开 >> Novartis Investigative Site Herston, Queensland, Australia, 4029 Australia, Victoria Novartis Investigative Site Melbourne, Victoria, Australia, 3000 Austria Novartis Investigative Site Vienna, Austria, A-1090 France Novartis Investigative Site Paris, France, 75010 Germany Novartis Investigative Site Berlin, Germany, 13353 Novartis Investigative Site Rostock, Germany, 18057 Israel Novartis Investigative Site Jerusalem, Israel, 91120 Novartis Investigative Site Ramat Gan, Israel, 5265601 Italy Novartis Investigative Site Firenze, FI, Italy, 50134 Novartis Investigative Site Varese, VA, Italy, 21100 Singapore Novartis Investigative Site Singapore, Singapore, 169608 Spain Novartis Investigative Site Madrid, Spain, 28041 United Kingdom Novartis Investigative Site Edgbaston, Birmingham, United Kingdom, B15 2WB Novartis Investigative Site London, United Kingdom, NW1 2BU Novartis Investigative Site London, United Kingdom, SE1 9RT 收起 <<
NCT02340780	Chronic Lymphocytic Leukemia	Phase 2	Active, not recruiting	June 2019	Canada, Alberta ... 展开 >> Tom Baker Cancer Centre Calgary, Alberta, Canada, T2N 4N2 Cross Cancer Institute Edmonton, Alberta, Canada, T6G 1Z2 Canada, Manitoba CancerCare Manitoba Winnipeg, Manitoba, Canada, R3E 0V9 Canada, Nova Scotia QEII Health Sciences Centre Halifax, Nova Scotia, Canada, B3H 1V7 Canada, Ontario University Health Network Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec The Jewish General Hospital Montreal, Quebec, Canada, H3T 1E2 收起 <<
NCT01923168	-		Completed	-	-
NCT02303041	Basal Cell Carcinoma (BCC) of ... 展开 >>the Skin Nevoid Basal Cell Carcinoma (BCC) Syndrome Recurrent Skin Cancer 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> Stanford University, School of Medicine Stanford, California, United States, 94305 收起 <<
NCT02088684	Breast Cancer	Phase 1 Phase 2	Completed	-	United States, Alabama ... 展开 >> University of Alabama at Birmingham/ Kirklin Clinic Dept Onc Birmingham, Alabama, United States, 35294-0006 United States, Massachusetts Dana Farber Cancer Institute Onc. Dept. Boston, Massachusetts, United States, 02215 United States, Tennessee Sarah Cannon Research Institute Onc Dept Nashville, Tennessee, United States, 37203 France Novartis Investigative Site Lyon Cedex, France, 69373 Italy Novartis Investigative Site Milano, MI, Italy, 20132 Novartis Investigative Site Modena, MO, Italy, 41124 Korea, Republic of Novartis Investigative Site Seoul, Korea, Korea, Republic of, 06351 Singapore Novartis Investigative Site Singapore, Singapore, 119228 Spain Novartis Investigative Site Madrid, Spain, 28050 Taiwan Novartis Investigative Site Taipei, Taiwan ROC, Taiwan, 10041 United Kingdom Novartis Investigative Site Leicester, United Kingdom, LE1 5WW 收起 <<
NCT01727128	Hepatic Impairment	Phase 1	Completed	-	Bulgaria ... 展开 >> Novartis Investigative Site Sofia, Bulgaria, 1618 Germany Novartis Investigative Site Berlin, Germany, 14050 Russian Federation Novartis Investigative Site Moscow, Russian Federation, 117198 收起 <<
NCT02756247	Lymphoma Mant... 展开 >>le Cell Lymphoma Follicular Lymphoma Diffuse Large B Cell Lymphoma 收起 <<	Phase 1	Active, not recruiting	May 2019	United States, New Jersey ... 展开 >> Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States, 07920 Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States, 07748 United States, New York Memorial Sloan Kettering Commack Commack, New York, United States, 11725 Memorial Sloan Kettering Westchester Harrison, New York, United States, 10604 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Memorial Sloan Kettering Rockville Centre Rockville Centre, New York, United States, 11570 收起 <<
NCT02117817	Ovarian Cancer ... 展开 >> Endometrial Cancer Recurrent Ovarian Cancer Recurrent Endometrial Cancer 收起 <<	Phase 1	Withdrawn(Research cancelled)	-	-
NCT02452294	Malignant Melanoma ... 展开 >> Metastases 收起 <<	Phase 2	Recruiting	July 2018	Germany ... 展开 >> Department of Dermatology, University Hopsital Recruiting Dresden, Germany, 01307 Contact: Friedegund Meier, MD ++49 351 458 ext 3677 Friedegund.Meier@uniklinikum-dresden.de Department of Dermatology, University Hospital Recruiting Tuebingen, Germany, 72076 Contact: Claus Garbe, MD ++49 7071 29 ext 87110 claus.garbe@med.uni-tuebingen.de Contact: Thomas Eigentler, MD ++49 7071 29 ext 85748 thomas.eigentler@med.uni-tuebingen.de 收起 <<
NCT01397877	Endometrial Cancer	Phase 2	Completed	-	France ... 展开 >> Clinique Bonnefon Ales, France Centre Paul Papin Angers, France Institut Ste Catherine Avignon, France Hôpital jean Minjoz Besancon, France Centre Hospitalier de Blois Blois, France Clinique Tivoli Bordeaux, France Institut Bergonié Bordeaux, France Polyclinique Bordeaux Nord Bordeaux, France centre Francois baclesse Caen, France Centre jean Perrin Clermont Ferrand, France Hôpitaux Civils de Colmar Colmar, France Centre Georges François leclerc Dijon, France Group Hospitalier Mutualiste de Grenoble Grenoble, France Hôpital Michallon - CHU Grenoble Grenoble, France CHD Les Oudairies la Roche sur Yon, France Hôpital André Mignot Le Chesnay, France Centre jean Bernard Le Mans, France Centre Oscar Lambret Lille, France CHU Dupuytren Limoges, France Centre Léon bérard Lyon, France Hôpital Prové Clairval Marseille, France institut Paoli Calmette Marseille, France CRLC Val d'Aurelle Montpellier, France, 34298 Groupement de coopération sanitaire Montpellier, France Centre Alexis Vautrin Nancy, France Centre d'oncologie de Gentilly Nancy, France Centre Catherine de Sienne Nantes, France Centre Antoine Lacassagne Nice, France CHU Caremeau Nimes, France Clinique Valdegour Nimes, France Centre Hospitalier Régional Orléans, France Hopital Hotel Dieu Paris, France, 75004 Hopital Tenon Paris, France, 75020 Centre Eugene Marquis Rennes, France Centre Frederic Joliot Rouen, France Centre Henri Becquerel Rouen, France Clinique Armoricaine de Radiologie Saint Brieuc, France Hôpital rené Huguenin St Cloud, France ICO René Gauducheau St Herblain, France Centre Etienne DOLET St Nazaire, France Institut cancérologuie de la loire St Priest en Jarez, France Hôpital Civil Strasbourg, France Centre Claudius Régaud Toulouse, France, 31052 CHU Bretonneau Tours, France Institut Gustave Roussy Villejuif, France 收起 <<
NCT01816984	Metastatic Squamous Neck Cance... 展开 >>r With Occult Primary Squamous Cell Carcinoma Recurrent Metastatic Squamous Neck Cancer With Occult Primary Recurrent Salivary Gland Cancer Recurrent Squamous Cell Carcinoma of the Hypopharynx Recurrent Squamous Cell Carcinoma of the Larynx Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity Recurrent Squamous Cell Carcinoma of the Nasopharynx Recurrent Squamous Cell Carcinoma of the Oropharynx Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Recurrent Verrucous Carcinoma of the Larynx Recurrent Verrucous Carcinoma of the Oral Cavity Salivary Gland Squamous Cell Carcinoma Stage IV Squamous Cell Carcinoma of the Hypopharynx Stage IV Squamous Cell Carcinoma of the Nasopharynx Stage IVA Salivary Gland Cancer Stage IVA Squamous Cell Carcinoma of the Larynx Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity Stage IVA Squamous Cell Carcinoma of the Oropharynx Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Stage IVA Verrucous Carcinoma of the Larynx Stage IVA Verrucous Carcinoma of the Oral Cavity Stage IVB Salivary Gland Cancer Stage IVB Squamous Cell Carcinoma of the Larynx Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity Stage IVB Squamous Cell Carcinoma of the Oropharynx Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Stage IVB Verrucous Carcinoma of the Larynx Stage IVB Verrucous Carcinoma of the Oral Cavity Stage IVC Salivary Gland Cancer Stage IVC Squamous Cell Carcinoma of the Larynx Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity Stage IVC Squamous Cell Carcinoma of the Oropharynx Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Stage IVC Verrucous Carcinoma of the Larynx Stage IVC Verrucous Carcinoma of the Oral Cavity Tongue Cancer 收起 <<	Phase 1 Phase 2	Active, not recruiting	June 2018	United States, Illinois ... 展开 >> University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637-1470 收起 <<
NCT01551030	Metastatic Transitional Cell C... 展开 >>arcinoma of the Urothelium 收起 <<	Phase 2	Active, not recruiting	March 2019	United States, New Jersey ... 展开 >> Memorial Sloan-Kettering at Basking Ridge Basking Ridge, New Jersey, United States, 07920 United States, New York Memorial Sloan-Kettering Cancer Center @ Suffolk Commack, New York, United States, 11725 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Memorial Sloan-Kettering Cancer Center at Mercy Medical Center Rockville Centre, New York, United States, 11570 Memoral Sloan Kettering Cancer Center@Phelps Sleepy Hollow, New York, United States 收起 <<
NCT01816594	HER2-positive, Newly Diagnosed... 展开 >>, Primary Breast Cancer, Neoadjuvant Therapy, Trastuzumab 收起 <<	Phase 2	Completed	-	Australia, New South Wales ... 展开 >> Novartis Investigative Site Concord NSW, New South Wales, Australia, 2139 Australia, Victoria Novartis Investigative Site Parkville, Victoria, Australia, 3050 Austria Novartis Investigative Site Salzburg, Austria, 5020 Germany Novartis Investigative Site Düsseldorf, Nordrhein Westfalen, Germany, 40235 Novartis Investigative Site Berlin, Germany, 13125 Novartis Investigative Site Dortmund, Germany, 44137 Novartis Investigative Site Erlangen, Germany, 91054 Novartis Investigative Site Essen, Germany, 45043 Novartis Investigative Site Essen, Germany, 45122 Novartis Investigative Site Gera, Germany, 07548 Novartis Investigative Site Kiel, Germany, 24105 Novartis Investigative Site Lübeck, Germany, 23538 Novartis Investigative Site Muenster, Germany, 48149 Novartis Investigative Site Offenbach, Germany, 63069 Singapore Novartis Investigative Site Singapore, Singapore, 119228 Spain Novartis Investigative Site Sevilla, Andalucia, Spain, 4103 Novartis Investigative Site Valencia, Comunidad Valenciana, Spain, 46010 Novartis Investigative Site Majadahonda, Madrid, Spain, 28222 Novartis Investigative Site Reus, Tarragona, Spain, 43204 收起 <<
NCT02048787	Renal Impairment	Phase 1	Completed	-	Bulgaria ... 展开 >> Novartis Investigative Site Sofia, Bulgaria, 1612 Czech Republic Novartis Investigative Site Praha 4, Czech Republic, 140 59 Germany Novartis Investigative Site Berlin, Germany, 14050 Romania Novartis Investigative Site Bucuresti, Romania 收起 <<
NCT01248494	Metastatic Breast Cancer	Phase 1	Completed	-	United States, Alabama ... 展开 >> University of Alabama Birmingham, Alabama, United States United States, Massachusetts Massachusetts General Hospital, Dana Farber Cancer Center Boston, Massachusetts, United States, 02114 United States, New York Columbia University Medical Center New York City, New York, United States United States, Tennessee Vanderbilt Cool Springs Nashville, Tennessee, United States, 37067 Vanderbilt Breast Center One Hundred Oaks Nashville, Tennessee, United States, 37204 Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232 收起 <<
NCT01719250	Recurrent Adult Diffuse Large ... 展开 >>Cell Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Refractory Mantle Cell Lymphoma Transformed Recurrent Non-Hodgkin Lymphoma 收起 <<	Early Phase 1	Completed	-	United States, Minnesota ... 展开 >> Mayo Clinic Rochester, Minnesota, United States, 55905 收起 <<
NCT01512251	BRAF Mutant Metastatic Melanom... 展开 >>a 收起 <<	Phase 1 Phase 2	Completed	-	United States, California ... 展开 >> University of California, San Francisco San Francisco, California, United States, 94115 收起 <<
NCT01363232	Advanced Solid Tumors ... 展开 >> Selected Solid Tumors 收起 <<	Phase 1	Completed	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Mass General 2 Boston, Massachusetts, United States, 02115 United States, Michigan Karmanos Cancer Institute Study Coordinator Detroit, Michigan, United States, 48201 United States, New York Memorial Sloan Kettering Cancer Center MSKCC (2) New York, New York, United States, 90033 United States, South Carolina Cancer Centers of the Carolinas CCC Faris Greenville, South Carolina, United States, 29605 United States, Texas University of Texas/MD Anderson Cancer Center MD Anderson PSC Houston, Texas, United States, 77030-4009 Canada, Ontario Array BioPharma Investigative Site Toronto, Ontario, Canada, M5G 2M9 Germany Array BioPharma Investigative Site Essen, Germany, 45147 Array BioPharma Investigative Site Heidelberg, Germany, 69120 Netherlands Array BioPharma Investigative Site Utrecht, Netherlands, 3584CX Singapore Array BioPharma Investigative Site Singapore, Singapore, 169610 Spain Array BioPharma Investigative Site Barcelona, Catalunya, Spain, 08035 Switzerland Array BioPharma Investigative Site Bellinzona, Switzerland, 6500 收起 <<
NCT01155453	Advanced and Selected Solid Tu... 展开 >>mors 收起 <<	Phase 1	Completed	-	United States, California ... 展开 >> University of California at Los Angeles Div. of Hematology/Oncology Los Angeles, California, United States, 90095 United States, Texas University of Texas/MD Anderson Cancer Center Dept of MD Anderson (8) Houston, Texas, United States, 77030-4009 Belgium Novartis Investigative Site Leuven, Belgium, 3000 Canada, Ontario Novartis Investigative Site Toronto, Ontario, Canada, M5G 2M9 Spain Novartis Investigative Site Sevilla, Andalucia, Spain, 41013 Novartis Investigative Site Barcelona, Catalunya, Spain, 08035 Switzerland Novartis Investigative Site Bellinzona, Switzerland, 6500 收起 <<
NCT01512251	-		Completed	-	-
NCT02614508	Recurrent Chronic Lymphocytic ... 展开 >>Leukemia Recurrent Small Lymphocytic Lymphoma Refractory Chronic Lymphocytic Leukemia Refractory Small Lymphocytic Lymphoma 收起 <<	Phase 1	Active, not recruiting	October 2022	United States, Georgia ... 展开 >> Emory University/Winship Cancer Institute Atlanta, Georgia, United States, 30322 收起 <<
NCT01283503	Advanced Solid Tumor	Phase 1	Completed	-	Japan ... 展开 >> Novartis Investigative Site Nagoya-city, Aichi, Japan, 466-8560 Novartis Investigative Site Kashiwa, Chiba, Japan, 277-8577 收起 <<
NCT01693614	Diffuse Large B-cell Lymphoma,... 展开 >> Mantle Cell Lymphoma, Follicular Lymphoma 收起 <<	Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 United States, Nebraska University of Nebraska Medical Center Univ Nebraska Omaha, Nebraska, United States, 68198 United States, New York Memorial Sloan Kettering Dept of Onc. New York, New York, United States, 10017 United States, South Carolina Medical University of South Carolina -Hollings Cancer Center Medical Univ of South Carolina Charleston, South Carolina, United States, 29425 United States, Texas University of Texas MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(3) Houston, Texas, United States, 77030 Belgium Novartis Investigative Site Brugge, Belgium, 8000 Novartis Investigative Site Yvoir, Belgium, 5530 France Novartis Investigative Site Marseille, France, 13273 Novartis Investigative Site Pierre-Benite Cedex, France, 69495 Novartis Investigative Site Rennes, France, 35019 Germany Novartis Investigative Site Frankfurt, Germany, 60590 Novartis Investigative Site Wurzburg, Germany, 97080 Italy Novartis Investigative Site Milano, MI, Italy, 20133 Novartis Investigative Site Milano, MI, Italy, 20141 Korea, Republic of Novartis Investigative Site Gyeonggi-do, Korea, Korea, Republic of, 10408 Novartis Investigative Site Seoul, Korea, Korea, Republic of, 06351 Spain Novartis Investigative Site Salamanca, Castilla Y Leon, Spain, 37007 Novartis Investigative Site Hospitalet de LLobregat, Catalunya, Spain, 08907 Turkey Novartis Investigative Site Izmir, Turkey, 35040 Novartis Investigative Site Samsun, Turkey, 55139 收起 <<
NCT01693614	-		Completed	-	-
NCT01289041	-		Completed	-	-
NCT02220855	Thymoma	Phase 2	Active, not recruiting	November 1, 2018	United States, Indiana ... 展开 >> Indiana University Simon Cancer Center Indianapolis, Indiana, United States, 46202 收起 <<
NCT01501604	Lung Cancer B... 展开 >>reast Cancer Colorectal Cancer Cholangiocarcinoma Solid Tumors 收起 <<	Phase 2	Withdrawn(The study has been c... 展开 >>losed due to lack of accrual) 收起 <<	-	-
NCT01610284	Breast Cancer	Phase 3	Active, not recruiting	December 31, 2018	-
NCT01723800	Recurrent Non-small Cell Lung ... 展开 >>Cancer Stage IV Non-small Cell Lung Cancer 收起 <<	Phase 1	Completed	-	United States, California ... 展开 >> City of Hope Medical Center Duarte, California, United States, 91010 收起 <<
NCT01540253	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, New York ... 展开 >> Roswell Park Cancer Institute Buffalo, New York, United States, 14263 收起 <<
NCT01289041	Advanced Endometrial Cancer	Phase 2	Completed	-	-
NCT01911325	Squamous Non-small Cell Lung C... 展开 >>ancer 收起 <<	Phase 1	Terminated(Review of safety an... 展开 >>d preliminary efficacy data showed marginal anti-tumor activity.) 收起 <<	-	United States, Arkansas ... 展开 >> Highlands Oncology Group SC-1 Fayetteville, Arkansas, United States, 72703 United States, Florida H. Lee Moffitt Cancer Center & Research Institute H Lee Moffitt Tampa, Florida, United States, 33612 United States, Massachusetts Reliant Medical Group Reliant Medical Group Worcester, Massachusetts, United States, 01608 United States, Virginia Virginia Oncology Associates Virginia Oncology Assoc. (2) Norfolk, Virginia, United States, 23502 Belgium Novartis Investigative Site Charleroi, Belgium, 6000 Novartis Investigative Site Mons, Belgium, 7000 France Novartis Investigative Site Creteil, France, 94000 Novartis Investigative Site Saint Herblain cedex, France, 44805 Germany Novartis Investigative Site Frankfurt, Germany, 60590 Novartis Investigative Site Heidelberg, Germany, 69120 Novartis Investigative Site Mainz, Germany, 55131 Italy Novartis Investigative Site Monza, MB, Italy, 20900 Korea, Republic of Novartis Investigative Site Seoul, Korea, Korea, Republic of, 05505 Novartis Investigative Site Seoul, Korea, Korea, Republic of, 06351 Spain Novartis Investigative Site Barcelona, Catalunya, Spain, 08036 Sweden Novartis Investigative Site Stockholm, Sweden, 171 76 收起 <<
NCT01626209	Advanced Breast Cancer, Advanc... 展开 >>ed Carcinomas With Squamous Cell Histology 收起 <<	Phase 1	Completed	-	China, Guangdong ... 展开 >> Novartis Investigative Site Guangzhou, Guangdong, China, 510030 China Novartis Investigative Site Beijing, China, 100021 Novartis Investigative Site Guangzhou, China, 510060 收起 <<
NCT01633060	Metastatic Breast Cancer	Phase 3	Completed	-	-
NCT02049541	Extranodal Marginal Zone B-cel... 展开 >>l Lymphoma of Mucosa-associated Lymphoid Tissue Nodal Marginal Zone B-cell Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Splenic Marginal Zone Lymphoma Waldenström Macroglobulinemia 收起 <<	Phase 1	Active, not recruiting	December 31, 2018	United States, Georgia ... 展开 >> Emory University Atlanta, Georgia, United States, 30322 United States, Ohio Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center Columbus, Ohio, United States, 43210 收起 <<
NCT01339442	Estrogen Receptor-positive Bre... 展开 >>ast Cancer Recurrent Breast Cancer Stage IV Breast Cancer 收起 <<	Phase 1	Completed	-	United States, Missouri ... 展开 >> Washington University School of Medicine Saint Louis, Missouri, United States, 63110 收起 <<
NCT01741753	Prostate Cancer	Phase 1	Terminated(Due to slow accrual... 展开 >> the supllier of BKM120 requested that we cease further enrollment.) 收起 <<	-	United States, Massachusetts ... 展开 >> Beth-Israel Deaconess Medical Center Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT01576666	Dose Escalation ... 展开 >> Safety Preliminary Efficacy Advanced Solid Tumors Metastatic Breast Cancer Advanced Pancreatic Adenocarcinoma Metastatic Colorectal Cancer Recurrent Glioblastoma Multiforme Gastric Cancer Gastroesophageal Junction Cancer Triple Negative Metastatic Breast Cancer Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer 收起 <<	Phase 1	Completed	-	-
NCT01572727	Breast Cancer	Phase 2 Phase 3	Completed	-	-
NCT01572727	-		Completed	-	-
NCT01470209	Solid Tumors ... 展开 >>Lung Cancer 收起 <<	Phase 1	Completed	-	United States, Georgia ... 展开 >> Winship Cancer Institute of Emory University Atlanta, Georgia, United States, 30322 收起 <<
NCT01820325	Non-Small Cell Lunch Cancer	Phase 1	Terminated(Due to DLTs/AEs saf... 展开 >>ety profile considered challenging.) 收起 <<	-	United States, Arkansas ... 展开 >> Highlands Oncology Group Fayetteville, Arkansas, United States, 72703 United States, Oregon Northwest Cancer Specialists Compass Oncology -BKM Portland, Oregon, United States, 97210 Canada, Ontario Novartis Investigative Site Toronto, Ontario, Canada, M5G 1Z6 Germany Novartis Investigative Site Ulm, Germany, 89081 Italy Novartis Investigative Site Napoli, Italy, 80131 Spain Novartis Investigative Site Barcelona, Catalunya, Spain, 08035 Novartis Investigative Site Madrid, Spain, 28046 收起 <<
NCT01068483	Breast Cancer ... 展开 >> Colon Cancer Ovarian Cancer Endometrium Cancer 收起 <<	Phase 1	Completed	-	United States, Tennessee ... 展开 >> Sarah Cannon Research Institute Dept.ofSarahCannonCancerCtr(4) Nashville, Tennessee, United States, 37203 Canada, Ontario Novartis Investigative Site Toronto, Ontario, Canada, M5G 2M9 Netherlands Novartis Investigative Site Rotterdam, Netherlands, 3015 CE Novartis Investigative Site Rotterdam, Netherlands, 3075 EA Spain Novartis Investigative Site Barcelona, Cataluna, Spain, 08035 收起 <<
NCT01339052	Glioblastoma	Phase 2	Active, not recruiting	August 2018	United States, California ... 展开 >> University of California, Los Angeles Los Angeles, California, United States, 90095 University of California, San Francisco San Francisco, California, United States, 94143 United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 United States, Texas UT, MD Anderson Cancer Center Houston, Texas, United States, 77030 United States, Utah Huntsman Cancer Institute, University of Utah Salt Lake City, Utah, United States, 84112 收起 <<
NCT01339052	-		Active, not recruiting	-	-
NCT01297491	-		Completed	-	-
NCT01468688	3rd Line GIST	Phase 1	Completed	-	United States, Massachusetts ... 展开 >> Dana Farber Cancer Institute SC (2) Boston, Massachusetts, United States, 02215 United States, Washington Seattle Cancer Care Alliance Onc Seattle, Washington, United States, 98105 Belgium Novartis Investigative Site Leuven, Belgium, 3000 Canada, British Columbia Novartis Investigative Site Vancouver, British Columbia, Canada, V5Z 4E6 France Novartis Investigative Site Lyon Cedex, France, 69373 Novartis Investigative Site Villejuif Cedex, France, 94805 Japan Novartis Investigative Site Kashiwa, Chiba, Japan, 277-8577 Netherlands Novartis Investigative Site Leiden, Netherlands, 2300 RC Spain Novartis Investigative Site Barcelona, Catalunya, Spain, 08035 United Kingdom Novartis Investigative Site London, United Kingdom, SW3 6JJ Novartis Investigative Site Manchester, United Kingdom, M20 9BX 收起 <<
NCT01473901	Glioblastoma	Phase 1	Completed	-	United States, Arkansas ... 展开 >> Highlands Oncology Group Highlands Oncology Fayetteville, Arkansas, United States, 72703 United States, Massachusetts Dana Farber Cancer Institute SC (1) Boston, Massachusetts, United States, 02215 United States, Texas University of Texas/MD Anderson Cancer Center MD Anderson DeGrout Houston, Texas, United States, 77030-4009 Australia, Victoria Novartis Investigative Site Melbourne, Victoria, Australia, 3000 Canada, Ontario Novartis Investigative Site Hamilton, Ontario, Canada, L8V 5C2 Novartis Investigative Site Toronto, Ontario, Canada, M5G 1Z6 Spain Novartis Investigative Site Barcelona, Catalunya, Spain, 08035 Novartis Investigative Site Madrid, Spain, 28040 收起 <<
NCT01634061	Castration-resistant Prostate ... 展开 >>Cancer 收起 <<	Phase 1	Completed	-	United States, California ... 展开 >> Cedars Sinai Medical Center SC Los Angeles, California, United States, 90048 United States, New Jersey Hackensack University Medical Center Hackensack Univ Hackensack, New Jersey, United States, 07601 Belgium Novartis Investigative Site Brussels, Belgium, BE-B-1200 Novartis Investigative Site Wilrijk, Belgium, 2610 Canada, British Columbia Novartis Investigative Site Vancouver, British Columbia, Canada, V5Z 4E6 France Novartis Investigative Site Marseille, France, 13273 Novartis Investigative Site Villejuif Cedex, France, 94805 Spain Novartis Investigative Site Barcelona, Catalunya, Spain, 08036 Novartis Investigative Site Madrid, Spain, 28041 United Kingdom Novartis Investigative Site Sutton, United Kingdom, SM2 5PT 收起 <<
NCT01304602	Colorectal Cancer	Phase 1	Completed	-	United States, Kansas ... 展开 >> University of Kansas Cancer Center Kansas City, Kansas, United States, 66160 收起 <<
NCT01790932	Breast Cancer	Phase 2	Active, not recruiting	December 2017	United States, Massachusetts ... 展开 >> Dana-Farber Cancer Institute at Faulkner Hospital Boston, Massachusetts, United States, 02130 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Brigham and Women's Hospital Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 收起 <<
NCT02000882	Brain Metastases ... 展开 >> Breast Cancer Metastatic Breast Cancer 收起 <<	Phase 2	Active, not recruiting	December 2018	United States, Texas ... 展开 >> Please contact Zuzanne Bristow for list of sites Multiple Locations, Texas, United States 收起 <<
NCT01629615	Breast Cancer	Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Dana-Farber at Faulkner Hospital Boston, Massachusetts, United States, 02130 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 Spain Hospital Universitario Vall d´Hebron Barcelona, Spain, 08035 Hospital Universitario 12 de Octubre Madrid, Spain, 28041 Instituto Valenciano de Oncología Valencia, Spain, 46009 Hospital Clínico Universitario de Valencia Valencia, Spain, 46010 收起 <<
NCT01297491	Non-small Cell Lung Cancer	Phase 2	Completed	-	-
NCT01830504	Thyroid Cancers	Phase 2	Unknown	January 2017	France ... 展开 >> Hospices Civils de Lyon Lyon, France, 69003 收起 <<
NCT01737450	Head and Neck Neoplasms ... 展开 >> Neoplasm Metastasis Recurrent Disease Progressive Disease 收起 <<	Phase 2	Recruiting	April 2020	France ... 展开 >> Hopital St André Recruiting Bordeaux, France Contact: Alain Ravaud 05 56 79 58 08 alain.ravaud@chu-bordeaux.fr Principal Investigator: Alain RAVAUD Sub-Investigator: Laurence DIGUE Sub-Investigator: Amaury DASTE Sub-Investigator: Denis SMITH Sub-Investigator: Nathalie TRUFFLANDIER Hôpital BEAUJON Not yet recruiting Clichy, France Contact: Sandrine FAIVRE, MD sandrine.faivre@bjn.aphp.fr Principal Investigator: Sandrine FAIVRE, MD Centre Oscar Lambret Recruiting Lille, France Contact: Gautier LEFEBVRE, MD +33 3 20 29 59 54 g-lefebvre@o-lambret.fr Contact: Gautier LEFEBVRE +33 3 20 29 59 54 g-lefebvre@o-lambret.fr Sub-Investigator: Audrey MAILLIEZ, MD Sub-Investigator: Cyril ABDEDDAIM, MD Principal Investigator: Gautier LEFEBVRE, MD Centre Léon Bérard Recruiting Lyon, France Contact: Jérome FAYETTE, MD jerome.fayette@lyon.unicancer.fr Principal Investigator: Jérôme FAYETTE, MD Sub-Investigator: Virginie AVRILLON, MD Sub-Investigator: Philippe CASSIER, MD Sub-Investigator: Alice LEVARD, MD Sub-Investigator: Eve-Marie NEIDHARDT, MD Sub-Investigator: Valérie PAULUS, MD Sub-Investigator: Philippe TOUSSAINT, MD Centre Val d'Aurelle - Paul Lamarque Recruiting Montpellier, France Contact: Didier CUPISSOL, MD didier.cupissol@montpellier.unicancer.fr Sub-Investigator: Catherine FAVIER, MD Principal Investigator: Didier CUPISSOL, MD Sub-Investigator: Dalila FERROUKHI, MD Sub-Investigator: Maryline LAIGRE, MD Sub-Investigator: Ernesto Jose LOPEZ MARTINEZ, MD Centre Antoine LACASSAGNE Recruiting Nice, France Contact: Frédéric PEYRADE, MD frederic.peyrade@nice.unicancer.fr Principal Investigator: Frédéric PEYRADE, MD Sub-Investigator: Christophe HEBERT, MD Sub-Investigator: Esma SAADA-BOUZID, MD Sub-Investigator: Jérôme BARRIERE, MD Sub-Investigator: Delphine BORCHIELLINI, MD Institut Curie Recruiting Paris, France Contact: Christophe LETOURNEAU, MD christophe.letourneau@curie.net Principal Investigator: Christophe LE TOURNEAU, MD Sub-Investigator: Véronique DIERAS, MD Sub-Investigator: Marie-Paule SABLIN, MD Centre Hospitalier Lyon Sud Recruiting Pierre Benite, France, 69003 Contact: Benoît YOU 04 78 86 43 18 benoit.you@chu-lyon.fr Principal Investigator: Benoît YOU Sub-Investigator: Amandine BRUYAS Sub-Investigator: Gilles FREYER Sub-Investigator: Salima HAMIZI Sub-Investigator: Sophie TARTAS Institut Gustave Roussy Recruiting Villejuif, France Contact: Caroline EVEN, MD +33 1 42 11 46 17 caroline.even@gustaveroussy.fr Contact: François-Régis FERRAND, MD francois-regis.ferrand@gustave.roussy.fr Principal Investigator: Caroline EVEN, MD Sub-Investigator: François-Régis FERRAND, MD Sub-Investigator: Margarida MATIAS, MD Sub-Investigator: Alfred SCHILF, MD Sub-Investigator: Lamia MAYACHE-BADIS, MD 收起 <<
NCT01953445	Breast Neoplasms	Phase 2	Withdrawn(The study sponsor fo... 展开 >>und the trial to be not viable.) 收起 <<	July 2015	-
NCT01613677	Treatment for Metastatic or Lo... 展开 >>cally Advanced Cervical Cancer 收起 <<	Phase 2	Withdrawn	September 2017	Brazil ... 展开 >> Novartis Investigative Site Rio de Janiero, RJ, Brazil, 20231-050 收起 <<
NCT01297452	Solid Tumors	Phase 1	Completed	-	United States, New York ... 展开 >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT01806649	Esophageal Cancer	Phase 2	Unknown	-	Thailand ... 展开 >> Songklanagarind Hospital, Prince of Songkla University Recruiting Hat yai, Songkhla, Thailand, 90110 Contact: Arunee Dechaphunkul, MD 6674 451469 dr.arunee@gmail.com Principal Investigator: Arunee Dechaphunkul, MD Sub-Investigator: Patrapim Sunpaweravong, MD Sub-Investigator: Jirawadee Sathitruangsak, MD Sub-Investigator: Lucksamon Thammalikitkul, MD Sub-Investigator: Teeravut Tubtawee, MD Sub-Investigator: Somkiat Sunpaweravong, MD Sub-Investigator: Kanet Kanjanapradit, MD 收起 <<
NCT02404844	Breast Cancer	Phase 2	Completed	-	Germany ... 展开 >> iOMEDICO AG Freiburg, Baden-Württemberg, Germany, 79108 收起 <<
NCT02035124	Advanced Prostate Cancer	Phase 2	Withdrawn(Study withdrawn due ... 展开 >>to slow accrual. No patients were enrolled.) 收起 <<	-	United States, Florida ... 展开 >> Florida Cancer Specialists-South Ft. Myers, Florida, United States, 33916 United States, Nebraska Nebraska Methodist Hospital Omaha, Nebraska, United States, 68114 United States, Tennessee Tennessee Oncology PLLC Nashville, Tennessee, United States, 37203 收起 <<
NCT02194049	Extensive Stage Small Cell Lun... 展开 >>g Cancer Unspecified Adult Solid Tumor, Protocol Specific 收起 <<	Phase 1	Completed	-	United States, California ... 展开 >> University of California at Davis Cancer Center Sacramento, California, United States, 95817 收起 <<
NCT01833169	PI3K Pathway Activated Tumors	Phase 2	Completed	-	-
NCT01396499	Leukemia	Phase 1	Completed	-	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01591421	Metastatic Colorectal Cancer	Phase 1 Phase 2	Active, not recruiting	December 2018	Canada, British Columbia ... 展开 >> BCCA - Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Ottawa Hospital Research Institute Ottawa, Ontario, Canada, K1H 8L6 Univ. Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT02301364	Lymphoma Prim... 展开 >>ary Central Nervous System Lymphoma Recurrent/Refractory Secondary Central Nervous System Lymphoma 收起 <<	Phase 2	Completed	-	United States, New Jersey ... 展开 >> Memoral Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States United States, New York Memorial Sloan Kettering Cancer Center @ Suffolk Commack, New York, United States, 11725 Memorial Sloan Kettering West Harrison Harrison, New York, United States, 10604 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT01623349	Ovarian Cancer ... 展开 >> Breast Cancer 收起 <<	Phase 1	Active, not recruiting	December 2019	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77230 收起 <<
NCT01833169	-		Completed	-	-
NCT01852292	Head and Neck Squamous Cell Ca... 展开 >>rcinoma 收起 <<	Phase 2	Terminated	-	-
NCT01852292	-		Terminated	-	-
NCT01870726	c-MET Inhibitor; PI3K Inhibito... 展开 >>r, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM 收起 <<	Phase 1 Phase 2	Terminated	-	United States, Massachusetts ... 展开 >> Dana Farber Cancer Institute SC Boston, Massachusetts, United States, 02215 United States, New York Columbia University Medical Center- New York Presbyterian Dept of Oncology New York, New York, United States, 10032 Memorial Sloan Kettering Cancer Center Neurology New York, New York, United States, 90033 United States, North Carolina Duke University Medical Center Duke - Baker Durham, North Carolina, United States, 27710 United States, Texas University of Texas MD Anderson Cancer Center SC-3 Houston, Texas, United States, 77030 Germany Novartis Investigative Site Bonn, Germany, 53105 Novartis Investigative Site Heidelberg, Germany, 69120 Novartis Investigative Site Tübingen, Germany, 72076 Netherlands ErasmusMC Cancer Institute - Neurooncology, RM G3-55 Rotterdam, Netherlands, 3075EA University Medical Center Utrecht, Rm Q05.4.300, P.O. Box 85500 Utrecht, Netherlands, 3508 GA Spain Novartis Investigative Site Barcelona, Catalunya, Spain, 08035 Novartis Investigative Site Madrid, Spain, 28041 Switzerland Novartis Investigative Site St. Gallen, Switzerland, 9007 收起 <<
NCT02301364	-		Completed	-	-
NCT01870726	-		Terminated	-	-
NCT01527877	Head Neck Cancer Squamous Cell... 展开 >> Metastatic Head Neck Cancer Squamous Cell Recurrent 收起 <<	Phase 2	Unknown	August 2014	Korea, Republic of ... 展开 >> Severance Hospital Recruiting Seoul, Korea, Republic of Contact: Byoung Chul Cho, MD 82-2-2228-8126 cbc1971@yuhs.ac Principal Investigator: Byoung Chul Cho, M.D., Ph.D. 收起 <<
NCT01571024	Advanced Solid Tumors ... 展开 >> Metastatic Colorectal Cancer Metastatic Pancreatic Cancer 收起 <<	Phase 1	Completed	-	United States, North Carolina ... 展开 >> University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States, 27599 收起 <<
NCT01349660	-		Active, not recruiting	-	-
NCT01487265	Non Small Cell Lung Cancer	Phase 2	Active, not recruiting	December 2017	United States, Florida ... 展开 >> Florida Cancer Specialists South Fort Myers, Florida, United States, 33916 Florida Hospital Cancer Institute Orlando, Florida, United States, 32804 Florida Cancer Specialists North Saint Petersburg, Florida, United States, 33705 Florida Cancer Specialists East West Palm Beach, Florida, United States, 33401 United States, Ohio Oncology Hematology Care, Inc. Cincinnati, Ohio, United States, 45242 United States, Tennessee Tennessee Oncology, PLLC Nashville, Tennessee, United States, 37023 United States, Texas Center for Cancer and Blood Disorders Fort Worth, Texas, United States, 76104 收起 <<
NCT01513356	Breast Cancer	Early Phase 1	Completed	-	Spain ... 展开 >> Hospital Madrid Norte Sanchinarro- CIOCC Madrid, Spain, 28050 收起 <<
NCT01589861	Breast Cancer	Phase 1 Phase 2	Suspended(Data analysis)	January 2018	France ... 展开 >> Institut Paoli-Calmettes Marseille, France, 13008 收起 <<
NCT01487265	-		Active, not recruiting	-	-
NCT01349660	Glioblastoma Multiforme	Phase 1 Phase 2	Active, not recruiting	February 2018	United States, Connecticut ... 展开 >> Yale School of Medicine New Haven, Connecticut, United States, 06520 United States, Florida Florida Cancer Specialists Fort Myers, Florida, United States, 33916 Florida Hospital Cancer Institute Orlando, Florida, United States, 32804 Florida Cancer Specialists Saint Petersburg, Florida, United States, 33705 United States, Maryland Center for Cancer and Blood Disorders Bethesda, Maryland, United States, 20817 United States, Michigan Grand Rapids Oncology Program Grand Rapids, Michigan, United States, 49503 United States, Nebraska Nebraska Methodist Hospital Omaha, Nebraska, United States, 68114 United States, Tennessee Tennessee Oncology Nashville, Tennessee, United States, 37203 收起 <<
NCT01695473	High Risk Prostate Cancer	Phase 2	Completed	-	United States, California ... 展开 >> University of California, San Francisco San Francisco, California, United States, 94115 收起 <<
NCT01385293	Prostate Cancer ... 展开 >> Metastatic (Spread to Other Areas of the Body) 收起 <<	Phase 2	Terminated(The trial was stopp... 展开 >>ed at the first stage due to futility) 收起 <<	-	United States, North Carolina ... 展开 >> Duke Cancer Institute Durham, North Carolina, United States, 27710 United States, Oregon OHSU Knight Cancer Institute Portland, Oregon, United States, 97239 United States, Washington University of Washington Seattle, Washington, United States, 98109 收起 <<
NCT01385293	-		Terminated(The trial was stopp... 展开 >>ed at the first stage due to futility) 收起 <<	-	-
NCT02439489	Solid Tumors	Phase 1	Completed	-	Italy ... 展开 >> Ospedale San Raffaele Milano, MI, Italy, 20100 收起 <<
NCT01550380	Endometrial Cancer	Phase 2	Withdrawn	-	United States, Utah ... 展开 >> Huntsman Cancer Institute Salt Lake City, Utah, United States, 84112 收起 <<
NCT02113878	Carcinoma, Squamous Cell of He... 展开 >>ad and Neck HPV Positive Oropharyngeal Squamous Cell Carcinoma Hypopharyngeal Cancer Early Invasive Cervical Squamous Cell Carcinoma Carcinoma of Larynx Cancer of Nasopharynx 收起 <<	Phase 1	Active, not recruiting	March 2020	United States, Massachusetts ... 展开 >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT01283048	Renal Cell Carcinoma	Phase 1	Completed	-	United States, Massachusetts ... 展开 >> Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Michigan Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States, 48201 收起 <<
NCT02128724	Carcinoma, Non-Small-Cell Lung	Phase 1	Completed	-	United Kingdom ... 展开 >> Churchill Hospital Oxford, Oxon, United Kingdom, OX3 7LE 收起 <<
NCT01570296	Non-Small Cell Lung Cancer ... 展开 >> Solid Tumors 收起 <<	Phase 1	Active, not recruiting	April 2019	Singapore ... 展开 >> National Cancer Centre Singapore Singapore, Singapore, 169610 收起 <<
NCT02487823	Non Castrate Metastatic Prosta... 展开 >>te Cancer 收起 <<	Phase 1	Terminated(Defect of recruitme... 展开 >>nt) 收起 <<	-	France ... 展开 >> Institut Paoli Calmettes Marseille, France, 13009 收起 <<

Buparlisib/布帕尼西 {[allProObj[0].p_purity_real_show]}

Buparlisib/布帕尼西纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Buparlisib/布帕尼西质控信息

Buparlisib/布帕尼西生物活性

Buparlisib/布帕尼西细胞实验

Buparlisib/布帕尼西动物实验

Buparlisib/布帕尼西动物研究

Buparlisib/布帕尼西临床研究

Buparlisib/布帕尼西参考文献

Buparlisib/布帕尼西实验方案

Buparlisib/布帕尼西技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Buparlisib/布帕尼西 {[allProObj[0].p_purity_real_show]}

Buparlisib/布帕尼西 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Buparlisib/布帕尼西 质控信息

Buparlisib/布帕尼西 生物活性

Buparlisib/布帕尼西 细胞实验

Buparlisib/布帕尼西 动物实验

Buparlisib/布帕尼西 动物研究

Buparlisib/布帕尼西 临床研究

Buparlisib/布帕尼西 参考文献

Buparlisib/布帕尼西 实验方案

Buparlisib/布帕尼西 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Buparlisib/布帕尼西纯度/质量文件产品仅供科研

Buparlisib/布帕尼西质控信息

Buparlisib/布帕尼西生物活性

Buparlisib/布帕尼西细胞实验

Buparlisib/布帕尼西动物实验

Buparlisib/布帕尼西动物研究

Buparlisib/布帕尼西临床研究

Buparlisib/布帕尼西参考文献

Buparlisib/布帕尼西实验方案

Buparlisib/布帕尼西技术信息